MetaCap

Cardio Diagnostics (CDIO) vs Insight Molecular Diagnostics (IMDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Insight Molecular Diagnostics is the larger company by market cap ($80.9 million vs $4.7 million), about 17.1 times the size. Insight Molecular Diagnostics converts more of its revenue into profit, with a net margin of -1238.5% versus -43832.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDIO-18.37%IMDX-43.06%
+3%-27%-57%
Oct 7, 20261 yearNov 20, 2026
CDIO-14.44%IMDX-41.54%
+3%-20%-44%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDIO versus IMDX key metrics
MetricCDIOIMDX
Share price$1.60$1.97
Market cap$4.74M$80.88M
1-day change-3.03%+18.67%
YTD return—-73.73%
1-year return—-67.38%
5-year return—-95.91%
EPS (TTM)$-2.52$-1.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.82K$4.05M
Revenue growth (YoY)-57.51%+115.58%
Net income (latest FY)$-6.50M$-50.22M
Gross margin—56.67%
Operating margin-43737.46%-1260.76%
Net margin-43832.49%-1238.52%
52-week high$7.91$7.51
52-week low$0.97$1.50
Distance from 52-week high-79.77%-73.77%
Analyst consensus—buy
Avg. price target upside—+318.78%
Average volume26.91K261.88K
Shares outstanding2.96M41.05M
Employees1555
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Insight Molecular Diagnostics is about 17.1 times larger than Cardio Diagnostics by market value ($80.88M vs $4.74M).
  • Insight Molecular Diagnostics is more profitable, keeping -1238.5 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
  • Insight Molecular Diagnostics grew revenue faster in its latest fiscal year (+115.58% vs -57.51%).

About Cardio Diagnostics

CDIO stock →

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees

About Insight Molecular Diagnostics

IMDX stock →

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees

CDIO vs IMDX FAQ

Which is bigger, Cardio Diagnostics or Insight Molecular Diagnostics?

Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $80.88M compared with $4.74M for Cardio Diagnostics (CDIO).

Are Cardio Diagnostics and Insight Molecular Diagnostics in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons